Article
In vivo CRISPR editing with no detectable genome-wide off-target mutations.
Nature - 1 Sept 2018
Akcakaya Pinar, Bobbin Maggie L, Guo Jimmy A, Malagon-Lopez Jose, Clement Kendell, Garcia Sara P, Fellows Mick D, Porritt Michelle J, Firth Mike A, Carreras Alba, Baccega Tania, Seeliger Frank, Bjursell Mikael, Tsai Shengdar Q, Nguyen Nhu T, Nitsch Roberto, Mayr Lorenz M, Pinello Luca, Bohlooly-Y Mohammad, Aryee Martin J, Maresca Marcello, Joung J Keith
Abstract excerpt
CRISPR-Cas genome-editing nucleases hold substantial promise for developing human therapeutic applications1-6 but identifying unwanted off-target mutations is important for clinical translation7. A well-validated method that can reliably identify off-targets in vivo has not been described to date, which means it is currently unclear whether and how frequently these mutations occur. Here we describe 'verification...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.